|Post IPO Valuation|
|Venture Round, 1/2011 |
New Enterprise Associates
|Private Equity, 1/2013 ||$86.4M|
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark. The Company is developing a portfolio consisting of four product candidates, including the compound, pimavanserin, which it is developing for three separate neurological and psychiatric indications in collaboration with Biovail Laboratories International SRL (Biovail), a subsidiary of Biovail Corp. The indications are Parkinsonâ€™s disease psychosis, which is in Phase III development, adjunctive therapy in schizophrenia, and Alzheimerâ€™s disease psychosis, for which it is initiating a Phase II feasibility study.